Insulin resistance - how important is it to treat?

Summary:

The ability of insulin to stimulate muscle glucose disposal and inhibit adipose tissue lipolysis is impaired in patients with type 2 diabetes. The progression from normal glucose tolerance and/or impaired glucose tolerance to type 2 diabetes only occurs when insulin secretory function declines to a degree that circulating insulin concentrations are no longer able to overcome muscle and adipose tissue insulin resistance. Although, ambient plasma insulin concentrations are not sufficiently high to maintain euglycaemia in patients with type 2 diabetes, absolute plasma insulin concentrations in these individuals are as high, if not higher, than in nondiabetic subjects. Since the plasma concentrations of insulin, or free fatty acids (FFAs), or both, are elevated in patients with type 2 diabetes secondary to muscle and adipose tissue insulin resistance, hypertriglyceridaemia is common in these individuals. Improvement in glycaemic control with insulin or insulin secretagogues is achieved by raising plasma insulin concentrations to a level high enough to overcome the insulin resistance. This is not the case with thiazolidinediones (TZDs): glycaemic control is associated with lower plasma insulin concentration. Compounds that improve insulin sensitivity and lead to lower glucose and insulin concentrations may have unique clinical benefit in the treatment of patients with type 2 diabetes.

Key words:

Insulin resistance - dyslipidaemia - coronary heart disease - thiazolidinediones

References

• 1 Carantoni M, Abbasi F, Chu L, Chen Y D, Reaven G M, Tsao P S, Varasteh B, Cooke J P. Adherence of mononuclear cells to endothelium in vitro is increased in patients with NIDDM.  Diabetes Care. 20 1462-1465 1997; 
• 2 Carpentier A, Mittelman S D, Lamarche B, Bergman R N, Giacca A, Lewis G F. Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation.  Am J Physiol. 39 E1055-E1066 1999; 
• 3 Chen N G, Abbasi F, Lamendola C, McLaughlin T, Cooke J P, Tsao P S, Reaven G M. Mononuclear cell adherence to cultured endothelium is enhanced by hypertension and insulin resistance in healthy nondiabetic volunteers.  Circulation. 100 940-943 1999a; 
• 4 Chen N G, Holmes M, Reaven G M. Relationship between insulin resistance, soluble adhesion molecules, and mononuclear cell binding in healthy volunteers.  J Clin Endocrinol Metab. 84 3485-3489 1999b; 
• 5 Chen N G, Reaven G M. Fatty acid inhibition of glucose-stimulated insulin secretion is enhanced in pancreatic islets from insulin-resistant rats.  Metabolism. 48 1314-1317 1999; 
• 6 Chen Y D, Reaven G M. Insulin resistance and atherosclerosis.  Diabetes Rev. 5 331-342 1997; 
• 7 Chen Y D, Swami S, Skowronski R, Coulston A M, Reaven G M. Effect of variations in dietary fat and carbohydrate intake on postprandial lipemia in patients with noninsulin dependent diabetes mellitus.  J Clin Endocrinol Metab. 76 347-351 1993; 
• 8 Feingold K R, Grunfeld C, Pang M, Doerrler W, Krauss R M. LDL subclass phenotypes and triglyceride metabolism in non-insulin dependent diabetes.  Arterioscler Thromb Vasc Biol. 12 1496-1502 1992; 
• 9 Fonseca V A, Valiquett T R, Huang S M, Ghazzi M N, Whitcomb R W. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: A randomized, controlled study. The Troglitazone Study Group.  J Clin Endocrinol Metab. 83 3169-3176 1998; 
• 10 Golay A, Zech L, Shi M Z, Chiou Y A, Reaven G M, Chen Y D. High density lipoprotein (HDL) metabolism in noninsulin-dependent diabetes mellitus: Measurement of HDL turnover using tritiated HDL.  J Clin Endocrinol Metab. 65 512-518 1987; 
• 11 Jones C N, Pei D, Staris P, Polonsky K S, Chen Y D, Reaven G M. Alterations in the glucose-stimulated insulin secretory dose-response curve and in insulin clearance in nondiabetic insulin-resistant individuals.  J Clin Endocrinol Metab. 82 1834-1838 1997; 
• 12 Leahy J L, Cooper H E, Deal D A, Weir G C. Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion. A study in normal rats using chronic in vivo glucose infusions.  J Clin Invest. 77 908-915 1986; 
• 13 Lehto S, Ronnemaa T, Pyorala K, Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with type II diabetes.  Diabetologia. 43 148-155 2000; 
• 14 Liu G C, Coulston A M, Lardinois C K, Hollenbeck C B, Moore J G, Reaven G M. Moderate weight loss and sulfonylurea treatment of non-insulin-dependent diabetes mellitus. Combined effects.  Arch Intern Med. 145 665-669 1985; 
• 15 Maggs D G, Buchanan T A, Burant C F, Cline G, Gumbiner B, Hsueh W A, Inzucchi S, Kelley D, Nolan J, Olefsky J M, Polonsky K S, Silver D, Valiquett T R, Shulman G I. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.  Ann Intern Med. 128 176-185 1998; 
• 16 Meigs J B, Mittleman M A, Nathan D M, Tofler G H, Singer D E, Murphy-Sheehy P M, Lipinska I, D'Agostino R B, Wilson P W. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.  JAMA. 283 221-228 2000; 
• 17 Paolisso G, Gambardella A, Amato L, Tortoriello R, D'Amore A, Varrichio M, D'Onofrio F. Opposite effects of short and long-term fatty acid infusion on insulin secretion in healthy subjects.  Diabetologia. 38 1295-1299 1996; 
• 18 Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland.  Diabetes Care. 2 131-141 1979; 
• 19 Pyorala K, Pedersen T R, Kjekshus J, Faergeman O, Olsson A G, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).  Diabetes Care. 20 614-620 1997; 
• 20 Raskin P, Rappaport E B, Cole S T, Yan Y, Patwardhan R, Freed M I. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.  Diabetologia. 43 278-284 2000; 
• 21 Reaven G M. Pathophysiology of insulin resistance in human disease.  Physiol Rev. 75 473-486 1995a; 
• 22 Reaven G M. The fourth musketeer - from Alexandre Dumas to Claude Bernard.  Diabetologia. 38 3-13 1995b; 
• 23 Reaven G M. Banting lecture 1988. Role of insulin resistance in human disease.  Diabetes. 37 1595-1607 1988; 
• 24 Reaven G M, Chen Y D, Hollenbeck C B, Sheu W H, Ostrega D, Polonsky K S. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance.  J Clin Endocrinol Metab. 76 44-48 1993; 
• 25 Reaven G M, Chen Y D. Role of insulin in regulation of lipoprotein metabolism in diabetes.  Diabetes Metab Rev. 4 639-652 1988; 
• 26 Reaven G M, Hollenbeck C, Jeng C Y, Wu M S, Chen Y D. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM.  Diabetes. 37 1020-1024 1988; 
• 27 Reaven G M, Mondon C E. Effect of in vivo plasma insulin levels on the relationship between perfusate free fatty acid concentration and triglyceride secretion by perfused rat livers.  Horm Metab Res. 16 230-232 1984; 
• 28 Ross R. The pathogenesis of atherosclerosis - an update.  N Engl J Med. 314 488-500 1986; 
• 29 Sacks F M, Pfeffer M A, Moye L A, Rouleau J L, Rutherford J D, Cole T G, Brown L, Warnica J W, Arnold J M, Wun C C, Davis B R, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.  N Engl J Med. 335 1001-1009 1996; 
• 30 Savage P J, Bennion L J, Flock E V, Nagulesparan M, Mott D, Roth J, Unger R H, Bennett P H. Diet-induced improvement of abnormalities in insulin and glucagon secretion and in insulin receptor binding in diabetes mellitus.  J Clin Endocrinol Metab. 48 999-1007 1979; 
• 31 Stanik S, Marcus R. Insulin secretion improves following dietary control of plasma glucose in severely hyperglycemic obese patients.  Metabolism. 29 346-350 1980; 
• 32 UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 352 837-853 1998; 
• 33 Weiland D, Mondon C E, Reaven G M. Evidence for multiple causality in the development of diabetic hypertriglyceridaemia.  Diabetologia. 18 335-340 1980; 
• 34 Yip J, Facchini F S, Reaven G M. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease.  J Clin Endocrinol Metab. 83 2773-2776 1998; 
• 35 Zavaroni I, Bonini L, Gasparini P, Barilli A L, Zuccarelli A, Dall'Aglio E, Delsignore R, Reaven G M. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: the Barilla factory revisited.  Metabolism. 48 989-994 1999;